The CONnective TIssue CAncers NETwork to integrate European Experience in Adults and Children (CONTICANET) is dedicated to improve the outcome of connective tissue cancers in adults, adolescents and children. Funded by the European Commission’s Sixth Framework Program (FP6-018806), this Network of Excellence kicked off in February 2006 for a five-year period. Ten work packages are grouped around the themes of “Integration” “Common research programme” and “Dissemination of excellence”. A consortium of 24 different organisations – cancer centres, academic institutions, patient advocacy groups and private enterprises – hailing from 9 countries (Belgium, France, Germany, Ireland, Italy, the Netherlands, Spain, Slovenia, UK), including > 250 researchers, is involved in collaborative research efforts that will help propagate excellence in the field. Improving the management of these tumours will come out the following outputs of the network activities:

Epidemiology

Molecular characterisation and nosological classification

Understanding the deviations of medical practices and initiating corrective strategies

Identifying new molecular targets and targeted treatments

Promoting clinical research on very rare subtypes

Addressing specific age (paediatrics, adolescents) or condition (Recklinghausen) group issues

Organisation of the collection and storage of biological samples

Standardisation of their management

Identification of centres of excellence for pathological and biological management and clinical management, and the scientific promotion of shared and multidisciplinary research programs.

In addition, CONTICANET will integrate the expertise from other networks through collaborations, such as clinical research networks (EORTC, National sarcoma groups), other networks (EUROBONET, networks on rare tumors and paediatric/adolescent tumors). Afyer 5 years a legal entity will continue to spread excellence in several directions: enlarging the network with academic and private organisations; continuing to enhance relations with EMEA, health authorities, patients advocacy groups, cancer leagues. Together, we aim to a European research foundation able to support integrated research actions and make available new treatments in these diseases.